Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02953457
Title Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

ovarian carcinoma

peritoneal carcinoma

fallopian tube carcinoma

Therapies

Durvalumab + Olaparib + Tremelimumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.